KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Net Income (2016 - 2025)

Historic Net Income for NovoCure (NVCR) over the last 12 years, with Q3 2025 value amounting to -$37.3 million.

  • NovoCure's Net Income fell 2191.69% to -$37.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$177.6 million, marking a year-over-year decrease of 1860.41%. This contributed to the annual value of -$168.6 million for FY2024, which is 1855.46% up from last year.
  • NovoCure's Net Income amounted to -$37.3 million in Q3 2025, which was down 2191.69% from -$40.1 million recorded in Q2 2025.
  • In the past 5 years, NovoCure's Net Income ranged from a high of -$4.1 million in Q1 2021 and a low of -$65.9 million during Q4 2024
  • Moreover, its 5-year median value for Net Income was -$34.3 million (2025), whereas its average is -$33.6 million.
  • Its Net Income has fluctuated over the past 5 years, first tumbled by 104183.34% in 2023, then surged by 4187.36% in 2024.
  • NovoCure's Net Income (Quarter) stood at -$26.5 million in 2021, then tumbled by 40.99% to -$37.3 million in 2022, then decreased by 26.21% to -$47.1 million in 2023, then plummeted by 40.02% to -$65.9 million in 2024, then soared by 43.46% to -$37.3 million in 2025.
  • Its Net Income stands at -$37.3 million for Q3 2025, versus -$40.1 million for Q2 2025 and -$34.3 million for Q1 2025.